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Biochemistry

Probing Isoforms of the Prion Protein through Tyrosine Nitration
Chairperson: Dr. Michele A. McGuirl
The prion protein (PrP) has multiple stable isoforms. When PrP misfolds, it aggregates
and causes neurological disease and death in mammals. The structure of the nonpathogenic isoform has been determined while the structures of the disease related
isoforms are unknown. The nitration labeling patterns of three PrP isoforms with
peroxynitrite and tetranitromethane, as detected by mass spectrometry, are reported. Two
conserved tyrosine residues (tyrosines 149 and 150) are not labeled by either reagent in
the normal cellular form of the prion protein but these residues become reactive after the
protein has been converted to one of two aggregated isoforms. Another difference
observed is that two other conserved tyrosine residues, 225 and 226, are much less
reactive in both aggregated isoforms, while all other tyrosine residues show virtually no
isoform specific-labeling. Thus, two regions been identified in which Tyr residues
undergo a change in solvent accessibility, which may be due to a conformational change
in that region or to inter-subunit packing
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CHAPTER 1: BACKGROUND
AND SIGNIFICANCE
Prion diseases are a class of fatal neurodegenerative disorders. A
number of different prion diseases occur in animals including, but not
limited to, Creutzfeldt-Jacob disease in humans, mad cow disease in
bovines, chronic wasting disease in deer and elk, and scrapie in sheep.
Interestingly, prion disorders may be inherited, sporadic or transmissible, a
characteristic in nature held only by prion diseases [1].
Prion diseases also belong to the larger category of amyloidoses,
which include Alzheimer's, Parkinson's, Huntington's and Amyotrophic
Lateral Sclerosis (ALS) diseases. In amyloidoses, misfolded proteins form
ordered aggregates in the central nervous system that are associated with
characteristic plaque formation and neurodegeneration [2].
The "protein-only" hypothesis of prion replication postulates that an
infectious, misfolded oligomeric prion protein particle (the “prion”) causes
the normal, non-infectious cellular form of the prion protein (PrPC) to
undergo a conformational change. This conversion event leads to the
incorporation of PrPC monomers into the infectious particle, referred to as
PrPSc [3].
Currently, the protein-only hypothesis has not been proven. The
key missing proof is the generation of infectious prions entirely in vitro [4].
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However, based upon the available data, the idea has generally been
accepted and three studies in particular have provided compelling support
of the protein-only hypothesis.
BÜeler and co-workers showed that knockout mice who do not
express PrPC appear to develop normally and are much less susceptible
to PrPSc infection than wild-type mice [5]. These data strongly suggest
that PrPC is needed to propagate the PrPSc infection. Furthermore, the
study found that heterozygous strains expressing less PrPC than usual
displayed significant resistance over wild-type mice to disease as well.
Legname and colleagues [6] injected recombinant amyloid fibrils
(PrPF) generated from murine PrP (residues 89-230) into transgenic mice
overexpressing PrPC of the same sequence and found the formation of
prion-like disease. Fibrils isolated from these mice were then able to
infect wild-type mice.
Unfortunately, the exact implications of the Legname study are
unknown because of problems in the experimental design and results [7].
Most striking is that the strain of mice used overexpress PrPC in such high
levels that they are able to develop the disease spontaneously. Also, the
infectivity of the recombinant fibrils was much less than that of normal
PrPSc.
Castilla et al. [8] have likely provided the most convincing data in
support of the protein-only hypothesis through a process called “protein
misfolding cyclic amplification” (PMCA), which attempts to mimic normal
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PrPSc propagation in vitro. Using a small amount of PrPSc purified from
hamster as a template, the authors generated infectious fibers in vitro from
PrPC purified from healthy hamster brain homogenate. In order to ensure
(as much as possible) that only in vitro fibrils were present, serial dilutions
were performed. Further supporting the claims of this study, a control
group which was inoculated with non-converted PrPC did not develop
disease.
The reason that the Castilla et al. study does not entirely prove the
protein-only hypothesis is that the PrPC from the brain homogenate of
healthy hamsters was used. Because this is the case, there is no way to
ensure that only PrPC was present for the template PrPSc to associate
with. In other words, there could be some necessary unknown factor, say
a virus, present in the brain homogenate.
Inherent in the protein-only hypothesis is that no bacteria or virus is
required for infection. More specifically, no DNA or RNA is required to
sustain the infection, just a supply of PrPC monomers. This lack of nucleic
acid appears to be unique to prion disorders among infectious diseases.
However, a recent study suggests that other amyloid protein deposits
have the potential to be infectious as well [9]. Mice over-expressing the
human Amyloid Precursor Protein became infected with an Alzheimer’s
like disease following intercranial inoculation with β-amyloid that was
isolated from humans with Alzheimer’s. In fact, all amyloid diseases
appear to share common structural characteristics and are capable of in
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vitro self propagation (like prions) [10]. Therefore, it is possible that if
given the opportunity, other amyloid plaque diseases would be infectious.
To explain the protein-only hypothesis, two models describing how
the correctly folded PrPC misfolds to form the pathogenic PrPSc have been
proposed. These two models are known as the refolding model and the
seeding model (figure 1-1) [11].

a) Refolding Model
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Figure 1-1. Models explaining the protein-only hypothesis (figure adapted
from reference 11).

The refolding model states that the conversion of PrPC monomers
to PrPSc is governed by a large activation energy barrier and does not
occur at detectable levels. However, upon interaction of PrPC with PrPSc,
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either from an exogenous (transmitted) or endogenous (inherited or
sporadic) source, PrPC partially unfolds and refolds through association
with PrPSc. Somehow through this unfolding and refolding process, the
thermodynamic barrier is able to be overcome.
The seeding model states that PrPC and an oligomeric precursor of
PrPSc are in an equilibrium with one another that highly favors the PrPC
isoform. Only when multiple PrPSc molecules are given a chance to
interact with one another is the pathogenic conformation stabilized and the
so called seed is able to form. In the case of infection by PrPSc particles,
the seed is what is transmitted. After the seed has been generated, the
addition of PrPC monomers to the PrPSc multimer is rapid.
PrPC is a soluble monomer dominated by α-helical structure while
PrPSc is an isoform enriched in β-sheet that forms insoluble fibrils and is
associated with infectivity [1]. PrPF are the recombinant PrP fibers
associated with much lower levels of infectivity [4]. Remarkably, no
covalent modifications occur during the conversion of PrPC monomers to
PrPSc fibrils; the difference between PrPC and PrPSc is purely
conformational [12]. Furthermore, the prion protein has the ability to form
at least one other distinct stable isoform. This third conformer, known as
the β-oligomer, is a soluble oligomer of 8-12 subunits that has a similar
secondary structure to PrPSc [13].
High resolution structures of PrPC from numerous mammals have
been determined by both NMR (figure 1-2) [14-22] and X-ray
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crystallography [23, 24]. In stark contrast, the tendency of all amyloid
fibers, including the infectious PrPSc, to form large heterogeneous
aggregates has hampered the elucidation of structural details. Figure 1-3
shows the gross structure and the fibrillar nature of PrPF. No NMR or
crystal structures of the β-oligomer currently exist either.

Helix 1

Helix 3

Helix 2
Amino Terminus

Figure 1-2. Structure of Syrian hamster PrPC amino acids 125-228 from
PDB 1B10 #4 [20], modified to include a representation of the intrinsically
unstructured amino terminus (amino acids 23-124). Secondary structure
is labeled by color (Red = α-helix, Blue = β-sheet, Grey = random coil and
turns)
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Figure 1-3. Electron micrograph of recombinant fibers made from Syrian
hamster PrP 90-232 (PrPF). Image was taken by the Rocky Mountain
Laboratories Electron Microscopy facility under the direction of Dr. Roger
Moore (Bar = 100 nm).

Although low resolution structural information of PrPSc has been
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gathered and many models of possible structures have been generated
(covered in detail in Chapter 5), crucial pieces of this puzzle are still
missing. Determining the structure of the infectious protein unit remains
one of the central mysteries in prion biochemistry. This is not only for
academic reasons, such as the light it could shed on the protein-only
hypothesis, but for practical reasons as well. Most importantly, this
knowledge could allow for the rational design of both prophylactics to
protect against initial infection, and treatments to halt or reverse the
neurodegeneration and certain death associated with prion diseases. But
even beyond the realm of prion disorders, because of the common
protofilament nature of amyloid deposits, a structure of PrPSc could
provide clues that lead to the prevention and treatment of all amyloid
plaque diseases.
Through our research, we seek to elucidate structural differences
between the recombinant PrPC, β-oligomer, and PrPSc of truncated Syrian
hamster PrP (residues 90 -232). We accomplished this task through the
selective nitration of some of the ten tyrosine (Tyr) residues found in this
domain and the determination of the modification sites using mass
spectrometry. Specifically, we first sought to determine the reactivity of
the Tyr residues in the recombinant soluble isoforms (PrPC and the βoligomer) of the prion protein using the nitrating reagents peroxynitrite
(PN) and tetranitromethane (TNM). Next, we sought to determine the
reactivity of the Tyr residues in the insoluble, recombinant fibrillar isoform
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(PrPF) of the prion protein with PN.
The rationale behind monitoring conformational changes through
the nitration of tyrosine residues is basically three-fold (expanded upon in
Chapter 6). First, nitration with PN and TNM is largely tyrosine-specific.
Next, nitration is dependent on the degree to which each tyrosine residue
is solvent exposed. Finally, Cashman and colleagues have detected an
increase in tyrosine solvent exposure and the emergence of a Tyr-Tyr-Arg
specific epitope upon PrPC conversion to PrPSc [25]. Therefore, we
hypothesize that structural differences among the three prion protein
isoforms will be detectable by the selective nitration of tyrosine residues
by PN and/or TNM. Furthermore, we hypothesize that more of the 10 Tyr
residues present will become nitrated upon conversion from PrPC to the βoligomer or PrPSc. By detecting these differences in nitration patterns, we
seek to provide crucial information about the structural differences that
take place as the innocuous PrPC converts to forms that resemble
infectious PrPSc.
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CHAPTER 2
MATERIALS AND METHODS
The overall experimental design is summarized as follows:

Express and Purify PrP90-232
Refold/Convert and Verify Isoform Structure
Treat with Peroxynitrite or Tetranitromethane
Verify that theIsoform Structural Integrity is Maintained
Determine the Nitration Patterns by Mass Spectrometry

Perform Comparative Data Analysis of Isoforms

Express and Purify PrP90-232 WT: The gene encoding truncated
WT Syrian Hamster PrP (residues 90-232, PrP90) was subcloned from the
pHaPrP plasmid [24] into the pET24a+ vector. The resulting new plasmid,
pET24PrP90, was transformed into E. coli BL21(DE3)-Rosetta cells
(Novagen, Inc.). The expressed protein did not contain most of the
unstructured amino-terminus, the GPI anchor, and was unglycosylated.
This work was performed by Sam J. Chelmo.
The antibiotics kanamycin (50 μg/mL) and chloramphenicol (34
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μg/mL) were added to select for transformed cells which were grown in
liquid culture at 37°C in 2xYT media. Growth was measured by optical
density at 600nm (OD600) and cell cultures were grown until the OD600
reached 1.0. At this point, the lactose analog isopropyl-β-Dthiogalactoside (IPTG) was added in order to induce expression. For each
liter of culture, 1 mL of 0.5M IPTG solution was added (to a final
concentration 0.5 mM). Expression levels were typically above 15 mg/L.
Following induction, cells were grown for 4 h, centrifuged, and frozen at 20°C overnight.
PrP90 was purified using modifications to a published procedure
[26]. This process began with lysis of the frozen cells by resuspension in
50 mM TrisHCl at pH 7.5 with 100 μg/mL lysozyme and 10 μg/mL DNase I
(lysis buffer). For every liter of cell culture originally grown, 50 mL of lysis
buffer was used. The suspension was shaken at 37°C until the
consistency was homogenous (~1.5 h) and the solution was then
centrifuged.
PrP90 is expressed as inclusion bodies. To purify the inclusion
bodies, the lysed cell pellet was resuspended in 50 mM TrisCl at pH 7.5
with 1% Triton X-100. After resuspension, the homogenate was placed on
ice for 20 min., and then centrifuged. This step was repeated 3-5 times
until the resulting pellet was a consistent white color.
Purified inclusion bodies were solubilized in buffer A (8 M urea, 0.1
M KPO4, pH 8.0 with100 μg/mL protease inhibitor cocktail from Sigma).
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The solution was once again centrifuged but in this case, the supernatant
contained PrP90. This supernatant was then mixed with a Ni(II)-Chelating
Sepharose resin (GE Healthcare) for 30 min. at room temperature to bind
the PrP90. For every liter of cell culture, 50 mL of resin was used. The
mixture of resin and PrP90 in buffer A was poured into a 5 cm diameter
column and washed with buffer A. Periodically, the absorbance at 280 nm
of effluent from the wash was measured and once the absorbance
dropped below 0.03, the washing was stopped. Next, a 1 L linear gradient
was set up to run from 100% buffer A to 100% buffer B (0.1 M KPO4, pH
8.0), which served to refold the PrP on the column. After completion of
the gradient, the column was washed with 100 mL of buffer B. Following
this, the refolded PrP90 (PrPC) was eluted from the column using buffer B
containing 60 mM imidazole.
If contaminating proteins were present, samples were subjected to
further purification using hydrophobic interaction chromatography (HIC)
using a HiPrep Phenyl Sepharose 16/10 column (GE Healthcare). Protein
was loaded onto the column in 6 M guanidine-HCl, 1 M NH4SO4, 10 mM
KPO4 at pH 8. To elute, a gradient from 1 M to 0 M NH4SO4 was run in the
presence of 4 M urea, 25 mM TrisCl at pH 8.0.
Purity, as well as possible protease digestion of PrP90 during
purification, were assessed after elution from the Ni(II)-chelating
Sepharose column by SDS/PAGE (and again if the HIC step was
necessary). Samples were mixed with TrisHCl pH 8 buffer containing
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SDS and the reducing agent dithiothreitol (DTT) and boiled at 95°C for 5
min. Following this treatment, samples were run on 8-25% polyacrylamide
gels using the Pharmacia PhastSystem (GE Healthcare). Coomassie blue
staining was also completed using the Pharmacia PhastSystem. The
BioRad broad range standards were used for mass determination. As
determined by SDS/PAGE, the purity level of protein used for all nitration
experiments was very high (figure 2-1.)

97.4 kDa

66.2

45

31

21.5

14.4
6.5

PrP 90
monomer
likely protease
cleaved PrP90

Figure 2-1. SDS/PAGE gel displaying the typical purity level of protein
used for reaction.

Refold/Convert and Verify Isoform Structure: Purified PrP90 was
either refolded to PrPC or converted to the β-oligomer or to the fibrillar
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form. To form PrPC, the PrP90 was dialyzed into 10 mM ammonium
acetate (NH4OAc) buffer at pH 5.5.
The β-oligomer was formed by the dilution of 120 μM protein
(initially in 6 M guanidine-HCl, 10 mM KPO4 at pH 8) to 20 μM with
conversion buffer (3.6 M urea, 160 mM NaCl, 60 mM NaOAc, pH 3.7) and
incubation overnight at 37°C. Following incubation, the β-oligomer was
dialyzed into 10 mM NH4OAc at pH 5.5.
Recombinant fibrils (PrPF) used were made by Dr. Roger Moore
from the laboratory of Dr. Sue Priola at Rocky Mountain Laboratories by
modifying a published procedure [13]. The PrPF was analyzed at RML
using electron microscopy and Fourier transform infrared spectroscopy
(FT-IR). PrPF used in these experiments was provided by Mr. Xu Qi and
Dr. Scott Hennelly.
Before and after reaction with PN or TNM, the conformation of PrPC
or the β-oligomer was verified by circular dichroism (CD) spectroscopy
using a Jasco 810 spectrophotometer and Asymmetric Flow Field Flow
Fractionation (AF4) using a Focus AF2000 with an in-line UV-visible
electronic absorbance detector (PostNova, Inc.).

CD is a technique that

distinguishes secondary structural characteristics and AF4 is a technique
that resolves particles into distinct peaks based on shape and mass.
The β-sheet and α-helix have distinct CD spectroscopic signatures
[27, 28]. In the case of β-sheet secondary structure, a single minimum is
observed at about 214 nm. As for α-helix secondary structure, two
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pronounced minima are observed at 222 nm and 209 nm.
When conducting an AF4 run, at least 400 pmol of sample were
injected and a 25 mM NaOAc, 3 M urea buffer at pH 5.0 was used
throughout the procedure. The focusing step took place on a 4 kDa
molecular weight cut off polyethersulfone membrane for 35 sec with
crossflow of 3 mL/min and a channel flow 1 mL/min. The peak resolution
step used a crossflow of 2 mL/min and a channel flow 1 mL/min.
Prior to nitration, PrPC and β-oligomer protein concentration was
determined by measuring the absorbance at 280 nm using an HP 8453A
photodiode array spectrophotometer, and the calculated extinction
coefficient of 26,025 M-1 cm-1 [29]. The Bio-Rad protein dye assay was
used after nitration due to the interference of nitrotyrosine absorbance
(figure 2-2). A protein standard curve was established vs. bovine serum
albumin (BSA) using unlabeled PrP, from which a correction factor of 0.93
was calculated. Following this, BSA was used as the standard reference
to determine PrP concentration. The structures of tyrosine and
nitrotyrosine are shown in figure 2-3.
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Absorbance (AU)

PN Treated β-Oligomer UV-Vis Spectrum
1.0
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Wavelength (nm)
Figure 2-2. UV-visible electronic absorbance spectra showing an increase
in absorbance at 280 nm and 360 nm of tyrosine residues upon nitration.
Measurements were taken in 10 mM NH4OAc, pH 5.5 and normalized to
the concentration of the unmodified PrP90 sample at 27 μM.

a

b

Figure 2-3. The structures of tyrosine (a) and nitrotyrosine (b).
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The concentration of PrPF was determined after denaturation in 6 M
guanidine-HCl, 10 mM KPO4 at pH 8 using the method of Pace et al [29].
PrPF concentration was not determined following nitration because CD
and AF4 could not be performed. Instead, the samples were used "as is"
for further work.
The percentage of common secondary structure motifs was
determined for PrPC and the β-oligomer by deconvolution of their CD
spectra. Measurements were taken from 185-240 nm at 20°C and 25
scans were averaged. Cuvettes of 0.1 or 0.2 mm path length and protein
concentrations from 7-14 μM of each isoform were used. Employing
reference set #3 of the CDSSTR program of the online DICHROWEB
server [27, 28], the percentages of secondary structures were calculated.
Reference sets are groups of proteins with known structures and CD
spectra used by DICHROWEB during deconvolution. Reference set #3
was used because it gave the result most consistent with the known
secondary structure of Syrian hamster PrPC [20].
For PrPC, solvent exposure and secondary structure levels were
assessed using MOLMOL software [30]. An average of the 25 best NMR
solution structures (PDB 1B10, reference 20) of recombinant Syrian
hamster PrPC was used in calculations.
The thermal denaturation of untreated, 100-fold peroxynitrite, and
1000-fold treated PrPC was measured using CD spectroscopy. Spectra
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were taken in the range of 190-300 nm at 2°C intervals from 25-85°C.

Treat with Peroxynitrite or Tetranitromethane: The nitrating
reagents peroxynitrite (PN) and tetranitromethane (TNM) were used to
label reactive Tyr residues in the different PrP isoforms. PN was
synthesized following a published procedure [31]. In this procedure, 20
mL of 0.6 M NaNO2, 0.9 M H2O2 was added to 10 mL HCl. Five to six
seconds later, 10 mL of 1.2 M KOH, and 400 μM
diethylenetriaminepentaacetic acid (DTPA) was added. To improve the
yield of potassium peroxynitrite, Dr. Scott Hennelly operated a SFM400
Biologic four-syringe quench flow system to mix the reagents (kindly
provided by Dr. Walt Hill). Typical concentrations of potassium
peroxynitrite obtained were 120 mM. After generation, the PN was stored
at -70°C. TNM was purchased from Sigma-Aldrich and stored at -70°C.
Special precautions were followed when using TNM (detailed below) due
to its extreme toxicity. Both PN and TNM were used in this study because
each reagent follows a different reaction mechanism (described in detail in
Chapter 6) and thus their reactivites can be influenced by different factors.
To check the concentration of PN, the reagent was first diluted 100fold in 1 M KOH and the UV-visible electronic absorbance spectrum was
measured. The PN concentration was checked periodically by measuring
the absorbance at 302 nm (extinction coefficient of 1670 M-1 cm-1) and no
detectable reduction in concentration occurred, even after 6 months.
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Several concentrations of each reagent were tested to ensure
effective nitration without secondary structure disruption and or significant
amounts of cross-linking, which is a side reaction of tyrosine nitration.
Mass spectrometry was performed on PrPC after treatment with 100-fold
PN, 150-fold PN, 250-fold PN, 100-fold TNM and 1000-fold TNM. For the
β-oligomer, samples treated with 100-fold and 250-fold excess of each
reagent were also analyzed by mass spectrometry. In the case of the
PrPF, samples reacted with 100-fold excess of PN were analyzed by mass
spectrometry.
All reactions were done in at least triplicate. The PrP90 soluble
isoforms were reacted at ~12 μM monomer protein concentration at pH
5.5 (the β-oligomer is unstable above pH 5.5). Treatments with PN used
200 mM 10 mM NH4OAc, 10 μM DTPA, pH 5.5. Samples were allowed to
react with PN for five minutes at room temperature.
The PrPF PN reaction buffer was 150 mM NH4OAc, 50 mM
NH4HCO3 at either pH 5.5 or pH 7.5 (3 reactions done at each pH). Prior
to reaction, the insoluble fibers were resuspended into a homogenous
solution at a final concentration of ~120 μM. As an added precaution,
reactions were performed under a biosafety laminar flow hood.
In the case of TNM, 50 mM NH4OAc, pH 5.5 buffer was used. PrPC
was reacted overnight while the β-oligomer was reacted for 2 hours at
room temperature. TNM was not reacted with PrPF due to time
constraints. Anaerobic conditions were employed during the TNM
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treatments and reactions took place under a standard chemical fume
hood.
Reactions intended to induce covalent cross-links were conducted
in the same buffer as nitration reactions. The excess of PN or TNM used
ranged from 250-fold to 1000-fold.
Following reaction of PrPC or the β-oligomer with PN or TNM,
byproducts were removed by dialyzing the samples into 10 mM NH4OAc,
pH 5.5. After PN reaction, PrPF was centrifuged and the pellet collected.
The sample was then denatured by resuspension in 8 M urea, 0.1 M
KPO4, pH 8.0 overnight at room temperature.

Verify Isoform Structural Integrity Maintained: Following PN or
TNM treatment and purification from reagents via dialysis, the soluble
isoforms were analyzed a second time by CD and AF4. In the case of
PrPF, the conformation was verified at RML using electron microscopy
prior to denaturation. These measurements were conducted to ensure
that no gross structural changes occurred as a result of the reaction.

Mass Spectrometry: In preparation for mass spectrometry, a 10%
trichloroacetic acid (TCA) precipitation was used to concentrate the PrPC
or the β-oligomer nitrated samples. In the case of PrPF, 30% TCA was
used following a 20-fold dilution of the denatured PrPF (the urea
concentration must be lowered for TCA precipitation to be successful).
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Protein pellets were washed with 1:1 ethanol:ether solution before being
re-suspended in 50 mM NH4HCO3 buffer at pH 8 and digested with trypsin
(1:7.5 trypsin to protein ratio suggested by Dr. Holly Cox). Tryptic
peptides expected are shown in table 2-1. Samples were digested
overnight at 37°C, reduced with DTT for one hour at 56°C and finally dried
under vacuum. Following this, samples were suspended in 80% ethanol
and dried under vacuum again.

22

Tryptic Peptides of PrP90
TyrosineContaining?

Mass
(Da)

Residues

P4 (Y169)

2475

165-185

PVDQYNNQNNFVHDCVNITIK

P1 (Y128)

2363

111-136

HMAGAAAAGAVVGGLGGYMLG
SAMSR

Internal Standard (IS)

1534

137-148

PMMHFGNDWEDR

P5 (Y218)

1457

209-220

VVEQMCTTQYQK

No

1283

90-101

GQGGGTHNQWNK

No

1153

195-204

GENFTETDIK

P3 (Y157, Y162, Y163)

1102

157-164

YPNQVYYR

P6 (Y225, Y226)

1088

221-229

ESQAYYDGR

No

1016

186-194

QHTVTTTTK

No

663

152-156

ENMNR

No

548

205-208

IMER

P2 (Y149, Y150)

501

149-151

YYR

No

493

107-110

TNMK

No

331

102-104

PSK

No

244

105-106

PK

No

193

230-231

SS

No

175

232

R

Peptide Sequence

Table 2-1. Peptides generated from PrP90 digest with trypsin ordered by
decreasing mass. Peptides containing tyrosine residues (P1-P6) are in
bold, as well as the peptide used as an internal standard (IS). This table
was generated using the PeptideCutter program[ 32].

Reduced peptides were re-suspended in 50% acetonitrile, 0.1%
trifluoroacetic acid and mixed in equal parts with the matrix α-cyano-4-
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hydroxycinnamic acid (CHCA) containing Bruker peptide standards I (table
2-2). Peptides were analyzed by Matrix Assisted Laser Desorption
Ionization-Time of Flight mass spectrometry (MALDI-TOF MS) using the
Applied Biosystems Voyager MALDI-TOF mass spectrometer. All mass
spectrometry was performed at the University of Montana Mass
Spectrometry and Proteomics Core Facility). Dr. Holly Cox performed
most of the MALDI-TOF mass spectrometry on the PrPC and the βoligomer isoforms.

Protein Standard

Mass (Da)

ACT clip 18-39

2465

ACT clip 1-27

2093

Bombesin

1619

Substance P

1347

Angiotensin I

1296

Angiotensin II

1046

Table 2-2. External protein standards used for calibration during MALDITOF MS (Bruker).

To assess the efficiency of the tryptic digests, a number of different
factors were analyzed. MALDI-TOF MS showed that most of the signal
arose from fragments smaller than 3000 amu, and there were no peaks in
the range of undigested PrP. Furthermore, between the range of 4505000 amu, well over 90% of the predicted tryptic peptides were identified.
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In most samples, no missed cleavages were seen, even in the case where
trypsin is less likely to cleave (when proline immediately follows lysine or
arginine).
The peptide composed of amino acids 209-220 containing Y218
was difficult to detect using MALDI-TOF MS. Therefore, a greater range
of error should be assumed for this peptide.
Prior to assessing the degree of nitration, raw spectra were
modified using the Data Explorer program (Applied Biosciences).
Employing the basic options of Data Explorer, the data were baseline
corrected, noise-filter smoothed, de-isotoped, and mass calibrated using
the Bruker standards.
The level of nitration for each Tyr-containing peptide was
determined as the percentage of all the nitrated species of a peptide
compared with all identified forms of the peptide. MALDI-TOF MS often
results in the loss of one or two oxygen atoms from the nitrotyrosine group
via photodecomposition [33]. Thus, the peak intensities of the un-nitrated
peptide, nitro peptide, nitro – 1 oxygen peptide, nitro – 2 oxygen peptide,
as well as possible methionine oxidized peptides were determined. (If
methionine is present, oxidation can occur, which adds an additional
oxygen to the peptide mass.) Once all forms of a peptide were identified
(see Appendix), the areas of the peaks derived from nitrated tyrosine
species were summed and then divided by the sum of all the peak
intensities.
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For this method of determining the level of nitration to be valid,
nitrotyrosine containing peptides must desorb from the matrix in the same
way as the corresponding unmodified and methionine-oxidized peptides.
To determine if this was true, a non-tyrosine containing prion peptide
(amino acids 137-148) was used as an internal standard. The total peak
intensity for each tyrosine-containing peptide, both in nitrated and
unnitrated samples, was compared with the intensity of the internal
standard. This analysis showed that there was no nitration-dependent
trends in matrix desorption.

Sequencing Electrospray Tandem Mass Spectrometry: To confirm
the site(s) of nitration on tryptic peptides containing more than one
tyrosine, sequence information was obtained by electrospray ionization
(ESI) tandem mass spectrometry (MS/MS) analysis using a QTOF micro
(Waters, Milford, MA). As the tryptic YYR peptide (residues 149-151) was
too small for ESI analysis, a cyanogen bromide digestion (table 2-3) was
performed instead. TCA precipitated protein pellets (15 μg) were mixed
with CNBr in 70% TFA at room temperature for 24 hours. The digestion
solution was removed under vacuum. Peptides from both trypsin and
cyanogen bromide digestion were resuspended in 2% acetonitrile, 0.1%
formic acid and separated by capillary liquid chromatography using a
CapLC XE (Waters) coupled to the ESI source of the QTOF micro. The
peptides were concentrated and desalted with an in-line C18 PepMap™
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Nano-Precolumn, 5 mm x 300 μm, 5 μm particle size (Dionex) followed by
reversed phase separation on a Waters C18 capillary column (15 cm x 75
μm i.d., 3 μm particle size). Peptides were eluted from the column with a
70-minute linear gradient of acetonitrile from 10-40% in 0.1% formic acid.
The voltages were set at 3800 V for the capillary, 38 V for the sample
cone and 3.0 V for the extraction cone. Mass spectra were acquired
between the range of 200-1500 m/z followed by data-dependent selection
of ions for MS/MS. To enhance the selection of low abundance
nitropeptides for MS/MS, only ions with m/z values that corresponded to
nitropeptide masses with a 2+ or 3+ charge state were selected for
collision induced dissociation fragmentation. Ions with m/z values
corresponding to the unmodified peptides were not selected for MS/MS.
Collision voltages were dependent upon the m/z and charge state of the
parent ion. MS/MS spectra were analyzed using Mascot Daemon (Matrix
Science) to search a database containing the hamster PrP90 sequence.
Methionine oxidation and nitrotyrosine were selected as variable
modifications. Mass accuracy was set to 50 ppm for peptide tolerance
and 0.2 Da for MS/MS tolerance. All ESI-MS/MS and CNBr digests were
performed by Dr. Holly Cox.
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CNBr Peptides
Mass
(Da)

Residues

Peptide Sequence

6156

155-206

NRYPNQVYYRPVDQYNNQNN
FVHDCVNITIKQHTVTTTTKGENFTET
DIKIM

2271

214-232

CTTQYQKESQAYYDGRRSS

2119

90-109

GQGGGTHNQWNKPSKPKTNM

1983
(P2b)

140-154

HFGNDWEDRYYRENM

1344

113-129

AGAAAAGAVVGGLGGYM

842

207-213

ERVVEQM

442

135-138

SRPM

430

130-134

LGSAM

367

110-112

KHM

102

139

M

Table 2-3. Peptides generated from PrP90 digest with CNBr ordered by
decreasing mass. P2b contains tyrosines 149 and 150.
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CHAPTER 3: PrPC
Adapted from Lennon et al., Biochemistry, 46, 4850-60, 2007.

Introduction
PrPC is a soluble monomer dominated by three α-helices, with two
short β-strands (see figure 1-2). PrPC contains a long intrinsically
unstructured amino-terminal domain comprised of amino acids 23 to ~108.
The protein normally resides on the external surface of cells, is mainly
neuronal, and contains a transitory signal peptide (amino acids 1-22) that
directs its delivery. It is attached to the plasma membrane by a
glycosylphoshatidylinositol (GPI) anchor, coded by amino acids 233-254
which are removed as part of the GPI processing [34].
Remarkably, the function of PrPC is not yet known. Further adding
to the mysterious nature of this highly conserved and abundant (in some
tissues) protein is that knockout mice not expressing any PrPC appear to
develop and behave normally [5], although their susceptibility to oxidative
stress may be higher than wild type mice [35].
Some basic facts are known about PrPC that are likely related to
function, two of which are best supported. First, the intrinsically
unstructured amino- terminus has the ability to bind copper (II) and thus
may serve some role in copper homeostasis [35]. Second, PrPC has
some protective function against oxidative stress and may serve to protect
the cell in that capacity [35].
Certain variations, germline and spontaneous mutations in the PrPC
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gene can lead to the formation of PrPSc and eventual death [36]. Germline
and sporadic mutations are also involved in the formation of other amyloid
diseases as well [37]. The most common human prion allelic variation is
at residue 129, which can be a methionine or valine. The presence of
valine at 129 appears to accelerate the misfolding of PrPC [38]. To review
some of the most frequent germline or sporadic mutations that result in
disease, we will consider three of these prion diseases; Fatal Familial
Insomnia (FFI), Creutzfeldt-Jakob disease (CJD) and GerstmannSträussler-Scheinker syndrome (GSS). When D178 is mutated to an
asparagine residue, FFI results [39]. If the M129V allele is present along
with the D178N mutation, then Creutzfeldt-Jakob disease develops.
Finally, when proline 102 is mutated to leucine, then GSS results .

Materials and Methods
A detailed description of the materials and methods used is
provided in Chapter 2. Briefly, PrPC was treated with varying levels of
peroxynitrite (PN) and tetranitromethane (TNM). Samples treated with
100-fold and 250-fold PN and TNM were analyzed by circular dichroism
(CD) and asymmetric flow field flow fractionation (AF4) to assess whether
structural changes had occurred. Matrix Assisted Laser
Desorption/Ionization mass spectrometry (MALDI-TOF MS) was
performed on the 100-fold PN and TNM treated samples to determine the
tryptic peptides that became nitrated. Sequencing of the peptides was
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done using Electrospray Ionization tandem mass spectrometry (ESI/MSMS) to determine which tyrosine residue was nitrated on peptides with
multiple tyrosines. Samples treated with up to 100-fold or 250-fold PN
were analyzed by SDS/PAGE to determine if any covalent cross-links
between PrP monomers were present. CD deconvolution was performed
to determine the secondary structure of PrPC using the DICHROWEB
online server. Solvent accessible surface area was performed using the
MOLMOL program.

Results
PrPC sensitivity to PN and TNM: PrPC is more sensitive to
treatment with PN than TNM. Analysis of the CD spectrum of PrPC fits
very well with the known structure and is consistent with previous
measurements. CD analysis shows a loss in α-helical secondary
structure with PN treatment above 100-fold, detected by a loss of negative
signal at 222 nm (figure 3-1). The formation of covalently linked higher
order aggregates is also observed with AF4 as the increase in absorbance
at higher retention times (figure 3-2) in PrPC treated with PN.
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Figure 3-1. CD spectrum of PN treated PrPC.
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Figure 3-2. AF4 trace of PN treated PrPC.
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In contrast, PrPC treated with 1000-fold TNM maintains its
secondary structure as measured by CD (figure 3-3). Furthermore, higher
order aggregates are not observed by AF4 (figure 3-4).

TNM Treated PrPC Circular Dichroism Spectra
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Figure 3-3. CD spectrum of TNM treated PrPC.
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Figure 3-4. AF4 trace of TNM treated PrPC.

Covalent cross-linking: The AF4 elution traces for 100 and 250-fold
PN treated PrPC show the formation of higher mass species (figure 3-2).
In the case of TNM treated PrPC, no higher mass species are observed,
even with 1000-fold treatment (figure 3-4). To test whether these higher
order aggregates were covalently cross-linked, SDS-PAGE was
performed. The results show that these higher mass species detected
after PN treatment are aggregates of covalently cross-linked, nonreducible PrPC monomers (figure 3-5).
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1
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4

5

97.4 kDa

66.2
Trimer
45

Dimer
31

21.5
Monomer
14.4
6.5

Figure 3-5. SDS/PAGE of PrPC. Lanes: BioRad SDS broad range protein
standard (1), Untreated PrPC (2), 250X PN treated PrPC (3), 250X TNM
treated PrPC (4), 1000X TNM treated PrPC (5).

PrPC nitration pattern with PN and TNM: PrPC labeling patterns
with 100-fold PN, 100-fold TNM and 1000-fold TNM are summarized in
Table 3-1. The level of nitration reported is an average of three separate
nitration experiments.
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Tryptic Peptide
Sequence
P1 (residues 111-136)
HMAGAAAAGAVVGGLGGY128MLGSAMSR
P2 (residues 149-151)
Y149Y150R

P3 (residues 157-164)
Y157PNQVY162Y163R

Mono-nitration
Di-nitration
Mono-nitration
Di-nitration
Tri-nitration

P4 (residues 165-185)
PVDQY169NNQNNFVHDCVNITIK
P5 (residues 209-220)
VVEQMCTTQY218QK
P6 (residues 221-229)
ESQAY225Y226DGR

Mono-nitration
Di-nitration

100x
PN

100x
TNM

1000x
TNM

PrPC

PrPC

PrPC

+

-

-

+
-

-

+
-

-

-

++

+++

-

+++

++++
++

+
-

++++
++

Table 3-1. MALDI/TOF analysis of Tyr-containing PrP peptides produced
by trypsin digestion. Nitration Key: -, 0 to 5% nitration; +, 6 to 20%
nitration; ++, 21 to 45% nitration; +++, 46-70%, ++++, 71 to 100%
nitration.

The nitration pattern of PrPC with 100-fold PN treatment (figure 3-6)
includes Y128, mono-nitration at either Y162 or Y163 on the 157-164
peptide, Y218, Y225 and Y226. Highest labeling occurs at the carboxyterminus of the protein, on the peptide containing Y225 and Y226. With
100-fold TNM treatment, little nitration was observed. Only a small
amount of mono-nitration on the 221-229 peptide containing two tyrosines
was detected. When PrPC was subjected to 1000-fold TNM treatment, a
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nitration pattern similar to 100-fold PN treatment was detected with two
exceptions. The 100-fold PN treatment led to nitration at Tyr128, without
nitration at Tyr169, while the 1000-fold TNM treatment led to nitration at
Tyr169, without nitration at Tyr128.

Figure 3-6. Structure of hamster PrPC [20] indicating the locations and
relative reactivities of the 10 Tyr residues after treatment with 100x PN.

A MALDI-TOF spectrum of peptides from the tryptic digest of PrPC,
after reaction with 100X PN (figure 3-7) as well as a portion of this
spectrum enlarged to show the nitration levels of the 157-164 and 221-229
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peptides (figure 3-8) is provided. The data for reaction with 1000X TNM
are similarly reported in figures 3-9 and 3-9. A mass table showing all of
the possible peptides of interest is provided in the appendix.

R e la tive In te n s ity
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Figure 3-7. A partial MALDI-TOF spectrum of peptides from the tryptic
digest of PrPC, after reaction with 100x PN. P2-P6 = tyrosine containing
tryptic peptides (P1 observed in different MALDI-TOF mode), IS = internal
standard, ES = Bruker external protein standards (listed in table 2-2).
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Figure 3-8. The partial MALDI-TOF spectrum in figure 3-7 showing the
peptides observed from loss of one or both oxygens from the nitro-group
as well as the levels of nitration for P3 and P6. P2-P6 = tyrosine
containing tryptic peptides (P1 observed in different MALDI-TOF mode),
IS = internal standard, ES = Bruker external protein standards (listed in
table 2-2).
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Figure 3-9. A partial MALDI-TOF spectrum of peptides from the tryptic
digest of PrPC, after reaction with 1000x TNM. P2-P6 = tyrosine containing
tryptic peptides (P1 observed in different MALDI-TOF mode), IS = internal
standard, ES = Bruker external protein standards (listed in table 2-2).
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Relative Intensity
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Figure 3-10. The partial MALDI-TOF spectrum in figure 3-9 showing the
loss of one or both oxygens from the nitro-group as well as the levels of
nitration for P3 and P6. P2-P6 = tyrosine containing tryptic peptides (P1
observed in different MALDI-TOF mode), IS = internal standard, ES =
Bruker external protein standards (listed in table 2-2).

Electro Spray Ionization Tandem Mass Spectrometry: Protein
sequencing using ESI/MS-MS was performed by Dr. Holly Cox for the
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peptides containing more than one tyrosine. Sequencing results indicate
that the 157-164 peptide could be labeled at Y162 or Y163, but no
nitration was observed at Y157. For the 221-229 peptide, nitration was
detected at both Y225 and Y226.

PrPC Solvent accessibility predictions by MOLMOL: Solvent
accessibility calculations were performed using MOLMOL software for the
PrPC Syrian hamster NMR structure PDB 1B10 [20], averaging the results
of all NMR structures. The labeling patterns with 100-fold PN and 1000fold TNM follows solvent accessibility predictions for most tyrosine
residues, with exception to Y218. The results of these calculations are
summarized in Table 3-2.

Tyrosine
residue

128

149

150

157

162

163

169

218

225

226

Nitration
Level
100X PN

+

-

-

-

+

+

-

+++

++++

++++

Nitration
Level
1000X
TNM
Solvent
accessible
surface
area (%)

-

-

-

-

+

+

++

+++

++++

++++
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59

5.6

13.7

2.8

2

11.7

3.3

16.4

5.6

Table 3-2: The Solvent Accessible Surface Area (SASA), as calculated
using the MOLMOL program for the average value for all NMR solution
structures from PDB #1B10 [20], is shown, along with the nitration levels
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for each tyrosine residue.

Thermal Stability: The thermal stabilities of wild-type, 100-fold PN
treated, and 1000-fold TNM treated PrPC were determined using CD.
While the untreated and 1000-fold TNM treated PrPC displayed similar
midpoint temperatures of unfolding of 68°C and near two-state behavior,
the 100-fold PN- treated sample unfolded at 58°C and deviated
significantly from two-state behavior (figure 3-11). As indicated earlier, the
level and pattern of nitration were similar between the 100-fold PN and
1000-fold TNM treated samples, except in relation to Y128 and Y169.
Also, some differences in the degree of methionine oxidation were
observed between the two samples. These results showed a higher level
of methionine oxidation in the PN treated sample.
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Figure 3-11. Thermal denaturation of PrPc before and after treatment with
100x PN or 1000x TNM, as followed by the loss in CD signal at 222 nm
(loss of α-helicity).

CD Deconvolution: The deconvolution of PrPc was performed and
the results are summarized in table 4-2. The amount of β-sheet
secondary structure was overestimated when compared to the NMR
structure, but otherwise the results were consistent.
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Discussion
In the case of PrPC, the availability of NMR structures provides a
structural framework to interpret the nitration results. By examining the
nitration patterns of PrPC in comparison with structural analysis, we can
draw conclusions about the factors influencing reactivity of the nitrating
reagents (PN and TNM mechanistic details described in Chapter 6).
Solvent accessibility as calculated by MOLMOL for the 1B10 NMR
structures of PrPC do not follow nitration patterns exactly, and therefore
should not be used to predict sites of nitration using PN or TNM. For
example, MOLMOL predicts that Y225 and Y226 are most solvent
accessible in PrPC, which is consistent with our results. Therefore, with
both PN and TNM, the most surface exposed residues in PrPC (Y225 and
Y226) are by far the most highly reactive. However, Y218 displays high
levels of reactivity and MOLMOL predicts that this residue is virtually
buried. One possible explanation for the reactivity of Y218 is that nitration
of Y225 and/or Y226 leads to a conformational change of Y218,
increasing its solvent accessibility.
When comparing the reactivity of PrPC toward PN and TNM, an
interesting result is found. PrPC is much less reactive toward TNM than
PN. Only low levels of mono-nitration are detected on the 221-230
peptide with 100-fold TNM in PrPC. Strikingly, a 1000-fold molar excess of
TNM is required to achieve a similar amount of nitration as detected with
100-fold PN. Initially, this result was not surprising due to the low pH of
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the reactions, which does not favor TNM reactivity. However, as
described in Chapter 4, 100-fold TNM nitrates the β-oligomer as efficiently
as 100-fold PN. Therefore, it is likely that pH is not influencing the
reactivity of TNM. The reason for this difference in TNM reactivity is
unknown, although one possible explanation is that the PrPC experiments
were performed early on, when inaccuracies in technique are more likely
to occur.
Unexpectedly, evidence has also been gathered suggesting that a
single tyrosine residue may play an important role in the stability of PrPC.
One important difference in the nitration patterns of PrPC with PN and
TNM is noted at Y128. Low levels of nitration at this tyrosine are detected
with 100-fold PN treatment, while no nitration at Y128 occurs even after
1000-fold TNM treatment. Temperature denaturation of wild type, 100-fold
PN, or 1000-fold TNM treated PrPC (figure 3-11) shows that the stability of
100-fold PN treated sample decreases considerably, while the 1000-fold
TNM treated sample does not change compared with the untreated
sample. Upon treatment of PrPC with >150-fold PN, a considerable loss in
α-helicity is measured by CD, which corresponds to an increase in
nitration at Y128. Possibly, a subset of the sample representing the
portion that is nitrated at Y128 unfoldd at lower temperatures, leading to
an overall decrease in α-helicity.
This result is not surprising, considering the wealth of data gathered
on the importance of methionine 129 in prion biology [38, 39]. M129 is
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adjacent to Y128, which forms a hydrogen bond with aspartate 178. If
nitration were to occur at Y128, it is possible that this could disrupt the
Y128/D178 hydrogen bond, leading to a decrease in overall protein
stability. It has been postulated that the D178N mutation in FFI
destabilizes PrPC for the same reason [40], further supporting this
conclusion. However, this claim cannot be definitively made because a
higher amount of methionine oxidation was also present in the PN-treated
samples (data not shown), and it is possible that increased oxidation of
the protein overall or at M129 caused the decrease in PrPC stability.
Chemical cross-links are observed by SDS/PAGE at high PN
concentrations. The CD spectra of these samples indicate that the protein
monomer is largely unfolded under these conditions. Therefore, the crosslinks are attributed to reactivity between Tyr residues of unfolded
monomers, as dityrosine formation has previously been observed as a
side reaction of nitration [41]. When the structure of PrPC is maintained,
cross-links between monomers do not form.
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CHAPTER 4: β-Oligomer
Adapted from Lennon et al., Biochemistry, 46, 4850-60, 2007.

Introduction
The β-oligomer is a soluble aggregated isoform (8-12 subunits) of
PrP rich in β-sheet secondary structure [13, 42, 43]. β-oligomers may be
formed from recombinant full length PrP lacking the GPI anchor [42], while
in other cases, such as ours, recombinant truncated lacking the GPI
anchor [13, 43]. The β-oligomer forms at low pH in denaturing conditions
(see Chapter 2). Following our procedure (modified from reference 13 by
Dr. Scott Hennelly), an octomer is formed (as determined by AF4 by Dr.
Scott Hennelly), which is consistent with previous studies [13, 43].
The β-oligomer shares secondary structural characteristics with
PrPSc, most notably a large increase in the amount of β-sheet character
upon conversion from PrPC [13, 43]. It should be noted that although the
β-oligomer is not believed to be on the kinetic pathway leading from PrPC
to PrPSc (i.e., not an intermediate) [13], it is however an aggregated form
of PrPC that is an intriguing model of PrPSc for a number of reasons.
Beyond the mere secondary structure similarity, the β-oligomer has been
shown to be toxic to neuronal cells [42], but is not infectious as with PrPSc.
The β-oligomer has also been shown to assemble into fibrils upon
prolonged incubation [43]. Furthermore, similarly sized particles (14-28
subunits) made from physical disruption and separation of PrPSc fibrils
were found to be more infectious than the large fibrils, per protein subunit
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[44].
As noted previously, detailed structures of PrPSc and the β-oligomer
have not been solved. Therefore, it cannot be stated that the β-oligomer
has a similar overall structure as PrPSc. However, we believe that the data
suggest that the β-oligomer may represent an important model for
studying the structure of PrPSc and, due to its superior tractability, is
worthy of biophysical investigation.

Materials and Methods
A detailed description of the materials and methods used is
provided in Chapter 2. Briefly, the β-oligomer was treated with varying
levels of peroxynitrite (PN) and tetranitromethane (TNM). Samples
treated with 100-fold and 250-fold PN and TNM were analyzed by circular
dichroism (CD) and asymmetric flow field flow fractionation (AF4) to
assess whether structural changes had occurred. Matrix Assisted Laser
Desorption/Ionization Mass Spectrometry (MALDI-TOF MS) was
performed on 100-fold PN and TNM treated samples to determine which
tryptic peptides became nitrated. Sequencing of the peptides was done
using Electrospray Ionization tandem mass spectrometry (ESI/MS-MS) to
determine which tyrosine residue was nitrated on peptides with multiple
tyrosines. Samples treated with up to 100-fold or 250-fold PN were
analyzed by SDS/PAGE to determine if any covalent cross-links between
PrP monomers were present. CD deconvolution was performed to
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determine the secondary structure of the β-oligomer using the
DICHROWEB online server.

Results
The β−oligomer does not show varying sensitivity levels to PN and
TNM: The β-oligomer does not display differing levels of sensitivity to
treatment with PN compared with TNM. Additionally, analysis of the CD
spectra does not indicated any significant protein unfolding with PN (figure
4-1), although some higher order aggregates were observed in the AF4
traces (figure 4-2. Similar results were obtained for TNM treatment at
either 100-fold or 250-fold molar excess (figure 4-3, figure 4-4).
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Figure 4-1. CD spectrum of PN treated β−oligomer.
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Figure 4-2. AF4 trace of PN treated β−oligomer.

Mean Residue Elipticy

TNM Treated β-Oligomer CD Spectra
0

-2000

Control
TNM100x

-4000

TNM 250x

-6000

-8000
200

220

240

Wavelength (nm)
Figure 4-3. CD spectra of TNM treated β−oligomer.
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Figure 4-4. AF4 trace of TNM treated β−oligomer.

Covalent cross-linking: The AF4 elution traces for 100 and 250-fold
PN or TNM treated β−oligomer show the formation of higher mass
species. SDS-PAGE on the 250X samples shows that these higher mass
species are aggregates of covalently cross-linked PrP (figure 4-5). In the
case of the β−oligomer, it was possible to determine whether covalently
cross-links were occurring within a single β−oligomer molecule. The AF4
peak at the elution time corresponding to the single β−oligomer subunit
was purified and subjected to SDS-PAGE. This analysis showed that
cross-links were forming within a single β−oligomer molecule (figure 4-5),
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Figure 4-5. SDS/PAGE of the β-oligomer. Lanes: BioRad SDS broad
range standard (1), Untreated β-oligomer (2), 100X PN treated β-oligomer
(3), 100X TNM treated AF4 purified β-oligomer (4).

The β−oligomer labeling pattern with PN and TNM: The β−oligomer
nitration patterns for 100-fold PN and 100-fold TNM treatment are
summarized in table 4-1. The results represent an average of three
separate nitration +experiments.
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Tryptic Peptide
Sequence
P1 (residues 111-136)
HMAGAAAAGAVVGGLGGY128M
LGSAMSR

100x
PN

100x
TNM

β-oligomer

β-oligomer

+

-

+++

+++

P2 (residues
149-151)
Y149Y150R

Mono-nitration
Di-nitration

-

-

P3 (residues
157-164)
Y157PNQVY162
Y163R

Mono-nitration

+
-

++
-

+

+

++

++

++

++

-

-

Di-nitration
Tri-nitration

P4 (residues 165-185)
PVDQY169NNQNNFVHDCVNITIK
P5 (residues 209-220)
VVEQMCTTQY218QK
P6 (residues
221-229)
ESQAY225Y226
DGR

Mono-nitration

Di-nitration

Table 4-1. MALDI/TOF analysis of Tyr-containing PrP peptides produced
by trypsin digestion. Nitration Key: -, 0 to 5% nitration; +, 6 to 20%
nitration; ++, 21 to 45% nitration; +++, 46-70%, ++++, 71 to 100%
nitration.

With 100-fold PN treatment, labeling occurred at Y128, mono-
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nitration on the 149-151 peptide containing two tyrosines, mono-nitration
on the 157-164 peptide containing three tyrosines, Y169, Y218, and
mono-nitration on the 221-229 peptide containing two tyrosines. At 100fold TNM treatment, the β−oligomer follows the same labeling pattern with
the exception of Y128, which was not labeled by TNM.
With both treatments, the highest levels of nitration occurred on
149-151 peptide, followed next by the 221-229 peptide. A MALDI-TOF
spectrum of peptides from the tryptic digest of the β−oligomer, after
reaction with 100X PN (figure 4-6) as well as a portion of this spectrum
enlarged showing the nitration levels of the 157-164 and 221-229 peptides
(figure 4-7) is provided. Figures 4-8 and 4-9 show the MALDI_TOF
spectra after reaction with 100X TNM.
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Figure 4-6. A partial MALDI-TOF spectrum of peptides from the tryptic
digest of the β−oligomer, after reaction with 100x PN. P2-P6 = tyrosine
containing tryptic peptides (P1 observed in different MALDI-TOF mode),
IS = internal standard, ES = Bruker external protein standards (listed in
table 2-2).
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Figure 4-7. The partial MALDI-TOF spectrum showing the loss of one or
both oxygens from the nitro-group for P6 as well as the overall levels of
nitration for P3 and P6. P2-P6 = tyrosine containing tryptic peptides (P1
observed in different MALDI-TOF mode), IS = internal standard, ES =
Bruker external protein standards (listed in table 2-2).
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Figure 4-8. A partial MALDI-TOF spectrum of peptides from the tryptic
digest of β−oligomer, after reaction with 100X TNM. P2-P6 = tyrosine
containing tryptic peptides (P1 observed in different MALDI-TOF mode),
IS = internal standard, ES = Bruker external protein standards (listed in
table 2-2).
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Figure 4-9. Portion of the partial MALDI-TOF spectrum in figure 4-8 to
show the loss of one or both oxygens from the nitro-group as well as the
levels of nitration for P3 and P6. P2-P6 = tyrosine containing tryptic
peptides (P1 observed in different MALDI-TOF mode), IS = internal
standard, ES = Bruker external protein standards (listed in table 2-2).

Electro Spray Ionization Tandem Mass Spectrometry: Protein
sequencing tandem MS-MS (ESI-MS/MS) was performed by Dr. Holly Cox
for the β-oligomer for peptides containing more than one tyrosine residue.
Sequencing results indicate that the 157-164 peptide labels at Y162 and
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Y163, with no nitration observed at Y157 (figure 4-10). Nitration is seen at
both Y225 and Y226 of the 221-229 peptide. In the case of Y149 and
Y150, both were reactive as well.

Figure 4-10. A sample ESI-MS/MS spectrum of one mono-nitrated P3
peptide (identified as nitroY162) from the 100-fold PN treated β-oligomer
sample. Inset: the masses of the M+H y ions expected from each of the
three potential sites of mono-nitration. (*) the loss of ammonia (-17) from R
or Q; (++) doubly charged ions.
CD Deconvolution: The deconvolution of the β-oligomer was
performed and the results are summarized in table 4-2. Because no
crystal or NMR structures are known for the β-oligomer, the precision of
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this deconvolution is unknown. However, it is clear that the amount of αhelix secondary structure was low and β-sheet secondary structure was
high.

PrPC

β-oligomer

Secondary
Structure
Type

From NMR

From CD

From CD

Helix

45%

36%

8%

β-sheet

6%

20%

33%

Turn

15%

19%

25%

Coil

34%

25%

34%

Table 4-2. Deconvolution analysis of the CD spectra of PrPC and the βoligomer using the online server DICHROWEB.

Discussion
Considering that low pH is predicted to inhibit the reactivity of TNM,
it is surprising that the β-oligomer reacts as efficiently with TNM as with
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PN at 100-fold excess. This is especially surprising because such high
levels of TNM were required to label PrPC. Furthermore, TNM causes
cross-linking in the β-oligomer (unlike PrPC) to a similar degree as with
PN. The β-oligomer is also able to withstand treatments of 250-fold PN
and TNM without any significant loss in secondary structure. These
results suggest that the β-oligomer is able to withstand higher levels of
nitration without unfolding when compared to PrPC.
As expected, the nitration pattern of the β-oligomer is different than
PrPC. Two areas in particular show a significant change upon
oligomerization. First, high levels of nitration are observed on the 149-151
peptide (containing the first YYR motif) which showed no reactivity in
PrPC. Next, much lower levels of nitration seen were seen at the three
carboxy-terminal tyrosine residues (Y225 and Y226). The implications of
these differences to PrPSc structure, as well as an in-depth comparison of
all the isoforms, is the subject of Chapter 6.
CD deconvolution shows that there is a large reduction in α-helix
and a large increase β-sheet secondary structure when PrPC converts to
form the β-oligomer (table 4-2). The predictions of secondary structure
derived from the deconvolution of the CD spectrum do not exactly match
NMR solution structure, although the α-helical content agrees well.
Clearly, a large decrease in α-helix occurs along with an increase β-sheet
secondary structure.
Remarkably, the FT-IR spectra of the β-oligomer and PrPF are
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nearly identical [43]. However, the amount of α-helix estimated by FT-IR
is much higher than that determined by deconvolution of the CD spectrum
of the β-oligomer. A possible explanation for this difference is that CD
spectroscopy more accurately estimates α-helix content while FT-IR
spectroscopy more accurately estimates β-sheet character [45].
The conclusion made in Chapter 3 that highly solvent exposed
tyrosine residues will likely become nitrated is important for interpreting
data for the β-oligomer and PrPF. In Chapter 6 where all the isoforms are
compared, the implications will be further discussed.
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CHAPTER 5: PrPF

Introduction
PrPSc is a isoform enriched in β-sheet secondary structure that
forms insoluble fibrils associated with infectivity [1]. As described earlier,
no NMR or crystal structures exist for PrPSc. PrPF is the recombinant form
of PrPSc fibers associated with much lower levels of infectivity [6].
Structural details of the PrPSc isoform as a whole have not yet been
determined, although regions have been determined to ~7 Ǻ [46]. As
described in Chapter 1, PrPSc forms large heterogeneous aggregates, and
so traditional methods such as NMR and X-ray crystallography have been
unsuccessful. A detailed structure of the PrPSc fiber subunits is of utmost
importance to the treatment and prevention of not only prion diseases, but
all amyloid plaque disorders in general. In this current study, we seek to
describe molecular level details of PrPF through nitration with peroxynitrite
(PN) coupled to mass spectrometry.
In the absence of a precise structure for PrPSc, many studies have
focused on elucidating gross PrPSc structural characteristics [47-60].
Atomic force microscopy and X-ray diffraction studies have revealed that a
common morphology exists for all amyloid fibrils [47, 48]. So called
“protofilaments”, with diameters ranging from 1.2-3.8 nm, intertwine with
one another to form the larger fibril structure. Regardless of the precursor
protein studied, these protofilaments appear to be the building blocks of all
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amyloid fibrils.
Using proteinase K, a non-specific serine protease that cleaves on
the carboxylic sides of aliphatic, aromatic or hydrophobic residues, it has
been shown that PrPC and PrPSc fibrils display differential digestion
profiles [48,49]. Specifically, while PrPC remains sensitive to complete
proteolysis, PrPSc fibrils are only subject to amino-terminal proteolysis and
form a resistant core from amino acids ~90-232. This finding as well as
amino-terminal deletion studies have led to the determination that aminoterminal region of the prion protein is not necessary to form PrPSc [53-55],
although it does influence the process [53-56].
Antibody studies have identified selective epitopes that are
exposed only in PrPSc [25, 57, 58]. In one antibody study carried out by
Cashman and colleagues [25], the investigators identified a YYR motif as
a PrPSc specific epitope. In the primary structure of PrP 90-232, two YYR
motifs are present at amino acids 149-151 and 162-164. Although the
study did not determine which motif became exposed upon conversion to
PrPSc, or if both YYR motifs were antigenic, the authors did favor
assignment to the second YYR (residues 162-164). In this same study,
using fluorescence spectroscopy, the authors suggest that upon
conversion from PrPC to PrPSc, more tyrosine residues become surface
exposed.
In another more recent study [58] using a number of different
antibody fragments and antibodies, it was shown that the region
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encompassing amino acids 132-156 was more immunogenic than regions
159-174 or 224-230 in PrPSc. These results suggest, contrary to
Cashmann and colleagues assessment, that the first and not the second
YYR motif is antigenic in PrPSc.
Fourier transform infrared spectroscopy (FT-IR) has indicated that a
large increase in β-sheet and a slight decrease in α-helix and random coil
secondary structure occurs in the transition from PrPC to PrPSc [59,
60]. As stated in Chapter 4, CD spectroscopy more accurately estimates
α-helix content while FT-IR spectroscopy more accurately estimates βsheet character [45]. Therefore, the amount of α-helix secondary structure
present in PrPSc may be much lower than FT-IR measurements suggest
and may be much closer to the β-oligomer.
Solid state NMR studies of the murine PrP89-113 peptide
confirmed that this region is entirely β-sheet when in the fibrillar form [46].
Low resolution 2-D electron crystallography has also been used to probe
PrPSc and found that the fibrils are consistent with parallel β-helices [60].
From data gathered in these studies and others, a number of
models have been proposed as the structure of the PrPSc subunits [61-68].
Although each of these models differs in the particular residues studied
and data used, every model proposes that interacting β-strands between
misfolded subunits serves as the mechanism of aggregation. Two of the
leading subunit models in the field are the β-spiral model [62] and the βhelix model [63]. Both models omit much of the protease sensitive amino-
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terminus and focus on the resistant core (residues 109-219 for the β-spiral
model and 90-228 for the β-helix model). Each predicts that the increased
β-sheet character occurs in amino-terminus of PrPC, leaving much of the
carboxy-terminal α-helical character unchanged. Figure 5-1 displays the
two different models.

Figure 5-1. The β-spiral model [61] and the β-helix model [62] for the PrPSc
fibril subunit. Figure is taken directly from reference 67(used with
permission).

The β-spiral model was generated by using molecular dynamics
simulations conducted under the cellular conditions, namely low pH, in
which the misfolding and aggregation of PrPC is thought to take place. The
β-spiral subunit consists of three α-helices and four β-strands. Three of
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the four β-strands form a small β-sheet, whereas the fourth β-strand is
located on a different face of the monomer. Interactions between the three
β-strands of one monomer and the lone β-strand from another monomer
form the subunit interface. Each subunit stacks on top of the next, growing
in a chain, to form a spiral reminiscent of a winding staircase.
The β-helix model was constructed after threading the prion
sequence onto several known β-sheet folds and choosing the fold that
best fit the available data. A fold known as the left-handed β-helix was
selected. The β-helix model predicts that the amino-terminus up to the
second α-helix (residues 90-175 in model) is essentially converted to a
left-handed β-helix (see figure 5-1). Three monomers come together such
that the left-handed β-helices form a core. Other trimers are proposed to
stack directly upon another to propagate the chain. It should be noted that
the energetics of this model have been called into question [68] because
of the lack of plausible interactions to hold the trimer subunits together,
and to stack them on top of one another.
The β-spiral model and β-helix model were compared recently by
Daggett and colleagues [68]. Although this comparison was objective, it
should be noted that the β-spiral model was constructed by DeMarco and
Daggett. In the assessment, the authors examined all of the experimental
data available and came to the conclusion that while the β-spiral model
was consistent with all, the β-helix model could not account for some of
the experimental data.
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For the same reason that it can’t be stated that the β-oligomer has
a similar overall structure as PrPSc, we must accept that is also true when
comparing PrPSc and PrPF. Again, no high resolution (within a 1.5-3 Ǻ)
molecular structures have been solved for PrPF. However, because PrPSc
and PrPF share more physical characteristics than PrPSc and the βoligomer and PrPF has been associated with infectivity [7], it is likely that
PrPF represents a better model of PrPSc.

Materials and Methods
A detailed description of the materials and methods used is
provided in Chapter 2. Briefly, PrPF was treated with varying levels of PN.
Samples treated with 100-fold PN were analyzed by electron microscopy
to ensure no structural changes had occurred and MALDI-TOF mass
spectrometry to determine which tryptic peptides became nitrated.
Samples treated with up to 1000-fold PN were analyzed by SDS/PAGE to
determine if any covalent cross-links between PrP monomers were
present.

Results
PrPF sensitivity to treatment with 100-fold PN : Following treatment
with 100-fold PN, electron micrographs were taken of PrPF. After
treatment, no change was detected in the structure of the fibrils according
to EM (figure 5-2).
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a

b

Figure 5-2. Electron micrographs of (a) untreated and (b) 100-fold
peroxynitrite treated (b) PrPF. Images were taken at the Rocky Mountain
Laboratories Electron Microscopy facility under the direction of Dr. Roger
Moore (Bar = 100 nm).

Covalent cross-linking: Covalent Cross-linked PrP monomers were
detected by SDS/PAGE following PrPF treatment with1000-fold PN at pH
7.5. 1000-fold PN was used to maximize the cross-linking reaction. No
mass spectrometry was performed on this sample.
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Figure 5-3. SDS/PAGE of PrPF. Lanes: 1000X PN treated PrPF (1),
Untreated PrPF (2), BioRad SDS broad range standard (3)

The PrPF labeling pattern with PN: The PrPF nitration patterns for
100-fold PN treatment is summarized in table 5-1. The levels indicated
represent an average for three separate experiments

Tryptic Peptide
Sequence

100x
PN
pH 5.5

100x
PN
pH 7.5
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P1 (residues 111-136)
HMAGAAAAGAVVGGLGGY128M
LGSAMSR

PrPF

PrPF

++

++

++

+++

P2 (residues
149-151)
Y149Y150R

Mono-nitration
Di-nitration

-

-

P3 (residues
157-164)
Y157PNQVY162
Y163R

Mono-nitration

+
-

+
-

-

-

+++

+++

++

++

-

-

Di-nitration
Tri-nitration

P4 (residues 165-185)
PVDQY169NNQNNFVHDCVNITIK
P5 (residues 209-220)
VVEQMCTTQY218QK
P6 (residues
221-229)
ESQAY225Y226
DGR

Mono-nitration

Di-nitration

Table 5-1. MALDI/TOF analysis of Tyr-containing PrP peptides produced
by trypsin digestion. Nitration Key: -, 0 to 5% nitration; +, 6 to 20%
nitration; ++, 21 to 45% nitration; +++, 46-70%, ++++, 71 to 100%
nitration.
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With 100-fold PN treatment at both pH 5.5 and pH 7.5, labeling
occurred at Y128, mononitration on the 149-151 peptide containing two
tyrosines, mononitration on the 157-164 peptide containing three
tyrosines, Y218, and mononitration on the 221-229 peptide containing two
tyrosines. The nitration pattern was the same at pH 5.5 and pH 7.5.
Sequencing of peptides containing multiple tyrosine residues has not been
performed for PrPF.
The highest levels of nitration occurred on the 149-151 peptide,
followed next by 111-136 and the 221-229 peptide. A partial MALDI-TOF
spectrum of peptides from the tryptic digest of the PrPF, after reaction with
100x PN, is provided for reference (figure 5-4). A portion of this spectrum
showing the nitration levels of the 157-164 and 221-229 peptides is also
provided (figure 5-5).
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Figure 5-4. A partial MALDI-TOF spectrum of peptides from the tryptic
digest of PrPF, after reaction with 100x PN. P2-P6 = tyrosine containing
tryptic peptides (P1 observed in different MALDI-TOF mode), IS = internal
standard, ES = Bruker external protein standards (listed in table 2-2).
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Figure 5-5. Portion of the partial MALDI-TOF spectrum in figure 5-4 to
show the loss of one or both oxygens from the nitro-group as well as the
levels of nitration for P3 and P6. P2-P6 = tyrosine containing tryptic
peptides (P1 observed in different MALDI-TOF mode), IS = internal
standard, ES = Bruker external protein standards (listed in table 2-2).
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Discussion
As expected, the nitration pattern of the PrPF is very different than
PrPC. Remarkably, PrPF and the β-oligomer have an almost identical
nitration pattern according to MALDI-TOF MS (without having sequencing
results to confirm). This provides strong evidence that the β-oligomer is a
good structural model of PrPF, and possibly PrPSc. The implications of
these isoform-dependent nitration patterns to prion biophysics, as well as
an in-depth comparison of all the isoforms, are the subject of Chapter 6.
The most important similarity between PrPF and the β-oligomer is
the high levels of nitration seen on the 149-151 peptide (containing the
first YYR motif) and the low levels of nitration seen on the 157-164 peptide
(containing the second YYR motif). The conclusion that the first, and not
the second YYR motif is the PrPSc specific epitope that was suggested by
the nitration pattern of the β-oligomer is now a much stronger claim. This
evidence is significant because, if extended to the structure of PrPSc, it
provides molecular level details of the aggregated isoform.
The labeling pattern of PrPF does not significantly change at the
two pH levels tested. This result is convenient because it allows us to
compare PrPF to the other isoforms (nitration done at pH 5.5) while still
conducting reactions at the physiological pH 7.5. Most importantly
reactions at pH 7.5 allow us to extend our comparisons to include PrPSc.
The electron micrographs of untreated and 100-fold PN treated
PrPF are not different. This is an important structural check to ensure that
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the PN treatment did not cause inter-fibril cross-links, which would appear
as clumping, or global unfolding of the fibrils, which would have appear as
the loss of fibrils.
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CHAPTER 6: COMPARING THE
DIFFERENT ISOFORMS
AND FUTURE DIRECTIONS

Comparing PrPC, the β-oligomer and PrPF
The normal prion protein cellular isoform (PrPC) and the disease
associated β-oligomer and PrPF isoforms were labeled at tyrosine
residues with peroxynitrite (PN) and tetranitromethane (TNM). These
experiments were done in an attempt to identify structural differences
among the three isoforms. From the results, two regions have been
identified that undergo substantial changes in the local chemical
environment upon the oligomerization of PrPC. These changes could be a
result of conformational changes between the isoforms, or conversely,
these changes could be due to the packing of PrP polypeptides in the
aggregated isoforms. Remarkably, these changes occur both when PrPC
aggregates to form either the soluble β-oligomer or fibrillar PrPF. Table 6-1
reports the nitration patterns of PrPC, the β-oligomer and PrPF following
treatment with 100-fold PN.

78
100x PN

PrPC

100x
PN
βoligomer

+

+

++

Mono-nitration

-

+++

+++

Di-nitration

-

-

-

Mono-nitration

+

+

+

Di-nitration

-

-

-

Tri-nitration

-

-

-

-

+

-

+++

++

+++

++++

++

++

++

-

-

100x
PN

Tryptic Peptide
Sequence
P1 (residues 111-136)
HMAGAAAAGAVVGGLGGY128MLGSAMSR
P2 (residues 149-151)
Y149Y150R
P3 (residues 157-164)
Y157PNQVY162Y163R

P4 (residues 165-185)
PVDQY169NNQNNFVHDCVNITIK
P5 (residues 209-220)
VVEQMCTTQY218QK
P6 (residues 221-229)
ESQAY225Y226DGR

Mono-nitration
Di-nitration

PrPF
pH 7.5

Table 6-1. MALDI/TOF analysis of Tyr-containing PrP peptides produced
by trypsin digestion. Nitration Key: -, 0 to 5% nitration; +, 6 to 20%
nitration; ++, 21 to 45% nitration; +++, 46-70%, ++++, 71 to 100%
nitration.

Within the PrP primary sequence, two YYR (149-151, 162-164) and
one YYD (225-227) motifs are present. A previous study using
monoclonal antibodies identified a YYR epitope exposed in PrPSc that is
buried in PrPC [25]. The most striking difference in nitration patterns
between PrPC and both the β-oligomer and PrPF is in the first YYR. Our
current work clearly shows that Y149 and Y150 only become reactive
toward nitration upon PrPC conversion to the β-oligomer or PrPF. In the
case of PrPF, it is not yet known which (or both) of the tyrosine residues
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becomes nitrated.
This finding is in contrast to the conclusions made by Paramithiotis
et al. [25], who contend that it is likely residues 162-164 that represent the
PrPSc exposed epitope. Our results show a similar, very low level of
mono-nitration at either Y162 or Y163 between PrPC and the β-oligomer
with 100-fold PN, 100-fold TNM (β-oligomer), and 1000-fold TNM (PrPC).
This same low level of mono-nitration is also detected on the 157-164
peptide of PN-treated PrPF (TNM was not tested). Nitration patterns
clearly suggest that the first YYR motif undergoes a dramatic change in
chemical environment upon aggregation while the second YYR does not.
The result could be due to conformational differences within a polypeptide,
packing between polypeptides of a protofibril, or packing between
protofibrils.
The nitration patterns of PrPC, the β-oligomer and PrPF point to
another region where significant structural change occurs - the carboxyterminus. Upon oligomerization, a reduction in reactivity occurs at Y225
and Y226 with both nitrating agents in the β-oligomer and PN with PrPF.
Reactivity is highest in PrPC at the 221-230 peptide (including large
amounts of dinitration), followed by Y218. In all isoforms, Y218 was
efficiently nitrated.
The patterns of nitration after 100-fold PN treatment are similar for
the β-oligomer and PrPF. Although it was expected that nitration patterns
would resemble one another, the nearly identical patterns suggest that
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common structural changes occur when PrPC converts to either of the βoligomer or PrPF isoforms. This result also argues against the notion that
the changes observed are simply due to subunit packing, rather than
conformational differences, as the packing is expected to be quite different
between the β-oligomer and PrPF.
From these results, we can confidently suggest that the β-oligomer
serves a valid model for studying PrPF and PrPSc. Further support of this
conclusion comes from the fact that FT-IR spectroscopy does not predict
α-helix secondary structure as well as CD spectroscopy [45]. Because the
FT-IR spectra of the β-oligomer and PrPF are nearly identical [43], it is
quite possible that the α-helical content of PrPSc is less than previously
reported 17-30% [59-60] and much closer to the 8% measured by CD
reported in Chapter 4.
The reactivity of PN or TNM toward a given tyrosine is dependent
on a number of factors [69]. Potassium peroxynitrite (K+ ONO2-) is stable
only at high pH. Upon exposure to an acidic environment, the protonation
.

.

of ONO2- induces the formation of NO2 and HO . The presence of these
radicals in the mixture can lead to hydrogen abstraction from a tyrosine
residue. Following the radicalization of tyrosine, reaction can occur
.

.

between Tyr and NO2 at the meta positions of the tyrosyl group (or a
cross-link between two Tyr radicals). Factors positively influencing the
reaction at a particular Tyr are solvent exposure, presence in a loop and
proximity to a negative charge or hydrophobic environment. Cysteines
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near the tyrosine will reduce the likelihood of nitration. A number of other
amino acids react with PN, including: oxidation of cysteine and
methionine residues, nitration of tryptophan, hydroxylation of
phenlyalanine and possible modification of histidine. Of these, only Met
oxidation was observed. When appropriate to determining sites of
nitration, the possible oxidation of methionine was accounted for.
TNM (C(NO2)4) nitrates tyrosine residues using a different
mechanism than that described for PN [70-71]. In the case of TNM, the
entire molecule encounters a tyrosine and a charge transfer complex
forms. Electrophilic attack leads to the formation of nitrotyrosine. As with
PN, protein cross-links can occur via the meeting of two tyrosine radicals.
Because this mechanism requires the initial abstraction of a proton from
the hydroxyl group of a tyrosine, the nitration rate increases as the pKa of
the Tyr residue decreases. This mechanism also suggests that the
reactivity of a Tyr should increase if it is involved in a hydrogen bond or is
proximal to a positive charge. Predicting the reactivity of a Tyr with TNM
is not cut and dry; the microenvironment of each residue must be
considered. One study found that the rate of reaction with TNM appears
to increase with surface exposure and decrease when the
microenvironment is negatively charged or hydrophobic [72]. However,
authors of an earlier study contend that the microenvironment drives TNM
reactivity independent of solvent exposure [70].
The complete absence of reactivity in PrPC at Y149 and Y150
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strongly suggests that an overall structural change must occur to make
both the β-oligomer and PrPF reactive at one or both of these residues.
When taken together with previous antibody work, Y149 and Y150 likely
represent a region of PrPC that undergoes significant structural change
during misfolding and oligomerization. The reduction in reactivity of the
carboxy-terminal tyrosines at positions 225 and 226 is also indicative of a
region in which a large structural change likely occurs upon
oligomerization or packing. Recent evidence using recombinant fibrils
suggests that the 224-230 epitope is buried under native conditions [58].
Residues 149-151 are located on helix 1 of the PrPC, a region that
is predicted to undergo complete transformation in the β-helix model [63].
Y149 and Y150 are predicted to be highly surface exposed in the β-helix
model as well. On the other hand, Y225 and Y226 are also highly surface
exposed in the β-helix model, which is not consistent with our results
(figure 6-1). Table 6-2 shows the predicted solvent accessible surface
area (SASA) for PrPC and the β-helix model.
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Figure 6-1. The β-helix model [61] with tyrosines 149 and 150 yellow
colored in and tyrosines 218, 225 and 226 colored in blue.

Tyrosine
residue

128

149

150

157

162

163

169

218

225

226

PrPC

5.6

13.7

2.8

2

11.7

3.3

16.4

5.6

39

59

1.1

42

40.2

44.3

12.3

43.9

31.5

38.5

59.6

58.6

SASA%
β-Helix
SASA%
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Table 6-2. Solvent accessible surface area (SASA) for PrPC, β-spiral
model, and the β-helix model. SASA calculations were generated by the
MOLMOL program using PDB coordinates from PrPC [20] and the β-helix
model [63].

To summarize our most important findings, we have identified two
regions of PrPC that undergo considerable conformational change in the
aggregation process. In both the aggregated isoforms studied, the βoligomer and PrPF, the chemical environments of the first YYR motif and
the carboxy-terminus are dramatically different from PrPC.

Future Studies
A number of future studies branching directly from these nitration
experiments will provide important structural details about PrPSc. This
information could be very useful in the construction of models of the
infectious PrPSc fibrils and thus give crucial information about the
formation of infectious prions.
First and foremost, sequencing mass spectrometry should be
performed on the 100-fold PN treated PrPF. Although this is more
completion of existing work than a future study, it is the needed step prior
to publishing the PrPF data and is currently being conducted in the McGuirl
laboratory. This data will show specifically which of the tyrosine residues
that are becoming nitrated in PrPF, as well as provide a better
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understanding of how closely related the β-oligomer is to PrPF.
Next, the nitration pattern of PrPSc should be characterized using
the same techniques described for PrPC, the β-oligomer and PrPF. This
will be more technically difficult, as PrPSc isolated from brain homogenate
is glycosylated, which could interfere with the nitration reagents. If quality
data could be gathered, then the information would provide molecular
level details of PrPSc and would be invaluable in assessing models of the
structure of PrPSc.
Another important set of experiments is to determine the crosslinking sites of the β-oligomer, PrPF, and possibly PrPSc. By exploiting this
side reaction as a stand-alone technique, the physical constraints of these
aggregated isoforms can be partially defined. The main problem
associated with this approach is that cross-linking is a side reaction and
obtaining enough sample to perform mass spectrometry may be difficult.
Even with enough sample, there are a large number of potential cross-link
sites (i.e., many masses to look for) that will complicate matters even
further.
Finally, antibodies should be used probe PrPC, the β-oligomer, PrPF
and PrPSc before and after nitration. By the disruption of binding at
selective epitopes, solvent accessibility can be more or less directly
correlated to nitration by PN and TNM. Although this approach appears
relatively straight-forward, the precise epitope to which an antibody binds
may not be clear, leaving the possibility for incorrect results.
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APPENDIX
Masses of Tyr-Containing PrP peptides and Respective
Nitration and Oxidized Methionine Derivatives
P1: 111-HMAGAAAAGAVVGGLGGYMLGSAMSR136

peptide
No
nitration
Nitro
Nitro
-1 Ox
Nitro
-2 Ox

+1
Oxidized
Met

+2
Oxidized
Met

2364
2409

2380
2425

2396
2441

2412
2457

2393

2409

2425

2441

2377

2393

2409

2425

P2: 149-YYR-151

P3: 157-YPNQVYYR-164

peptide
No
nitration
Nitro
Nitro
-1 Ox
Nitro
-2 Ox
Di-nitro
Di-nitro
-1 Ox
Di-nitro
-2 Ox

+3
Oxidized
Met

501
546
530
514
591
575
559

Peptide
No
nitration
Nitro
Nitro
-1 Ox
Nitro
-2 Ox
Di-nitro
Di-nitro
-1 Ox
Di-nitro
-2 Ox
Tri-nitro
Tri-nitro
-1 Ox
Tri-nitro
-2 Ox

1103
1148
1132
1116
1193
1177
1161
1238
1222
1206

P4: 165PVDQYNNQNNFVHDCVNITI-185

peptide
No
nitration
Nitro
Nitro
-1 Ox
Nitro
-2 Ox

2476
2521
2505
2489

P6: 221-ESQAYYDGR229

Peptide
No
nitration
Nitro
Nitro
-1 Ox

1088
1133
1117
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P5: 209-VVEQMCTTQYQK-220

peptide
No
nitration
Nitro
Nitro
-1 Ox
Nitro
-2 Ox

1metox

1458

1474

1503

1519

1487

1503

1471

1487

nitro-2ox
Di-nitro
Di-nitro
-1 Ox
Di-nitro
-2 Ox

1101
1178
1162
1146
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